Analysts predict that Bio-Techne (NASDAQ:TECH) will report earnings per share of $1.14 for the current quarter, Zacks reports. Five analysts have made estimates for Bio-Techne’s earnings. The highest EPS estimate is $1.21 and the lowest is $1.05. Bio-Techne posted earnings of $0.97 per share in the same quarter last year, which would suggest a positive year over year growth rate of 17.5%. The business is expected to issue its next quarterly earnings results before the market opens on Wednesday, May 2nd.
On average, analysts expect that Bio-Techne will report full year earnings of $4.32 per share for the current fiscal year, with EPS estimates ranging from $4.07 to $4.51. For the next fiscal year, analysts forecast that the firm will post earnings of $4.90 per share, with EPS estimates ranging from $4.52 to $5.15. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Bio-Techne.
Bio-Techne (NASDAQ:TECH) last posted its quarterly earnings results on Tuesday, February 6th. The biotechnology company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.92 by $0.10. Bio-Techne had a net margin of 19.17% and a return on equity of 14.39%. The company had revenue of $154.15 million during the quarter, compared to analyst estimates of $145.93 million. During the same period last year, the firm posted $0.81 EPS. Bio-Techne’s revenue for the quarter was up 16.9% compared to the same quarter last year.
TECH traded up $1.54 during trading on Thursday, reaching $151.47. 62,402 shares of the company’s stock were exchanged, compared to its average volume of 178,770. Bio-Techne has a 1 year low of $99.96 and a 1 year high of $151.96. The company has a current ratio of 3.10, a quick ratio of 2.49 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $5,581.75, a PE ratio of 43.84, a P/E/G ratio of 2.48 and a beta of 0.70.
In other Bio-Techne news, Director Charles A. Dinarello sold 5,000 shares of Bio-Techne stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $136.06, for a total transaction of $680,300.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 3.40% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in TECH. Financial Gravity Companies Inc. acquired a new stake in Bio-Techne during the 4th quarter worth $118,000. Advisory Services Network LLC boosted its position in shares of Bio-Techne by 1,423.3% during the 4th quarter. Advisory Services Network LLC now owns 1,112 shares of the biotechnology company’s stock valued at $144,000 after acquiring an additional 1,039 shares during the last quarter. Advisor Group Inc. boosted its position in shares of Bio-Techne by 64.5% during the 4th quarter. Advisor Group Inc. now owns 1,288 shares of the biotechnology company’s stock valued at $167,000 after acquiring an additional 505 shares during the last quarter. Zions Bancorporation acquired a new position in shares of Bio-Techne during the 3rd quarter valued at about $178,000. Finally, Gofen & Glossberg LLC IL acquired a new position in shares of Bio-Techne during the 4th quarter valued at about $205,000. 97.14% of the stock is currently owned by institutional investors.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates through three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.